Phaseline

Companies › Isofol Medical

Isofol Medical: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Nov 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Arfolitixorin
5,10-methenyltetrahydrofolate synthetase inhibitor; active metabolite of leucovorin for 5-
MTHFRPhase 1Metastatic Colorectal Cancer (mCRC)Nov 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06922383ArfolitixorinPhase 1Metastatic Colorectal Cancer (mCRC)OncologyNov 2028

Targets

MTHFR (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.